EDENT1FI European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease Interception
- Coordinator
- Katholieke Universiteit Leuven, Belgium
- Runs
- 1 November 2023 to 31 October 2028
- Status
- Running
- EU funding
- €10.7m
- Total cost
- €22.2m
- Partners
- 37 organisations in 14 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101132379
What the project is doing
In the project's own words, from its summary on CORDIS.
EDENT1FI is a unique and timely project building and operationalising an open platform for general population screening of children/adolescents for type 1 diabetes (T1D) throughout Europe. The case is compelling: T1D is a common chronic disease affecting >1 in 300 children or adolescents. Decades of European research have signposted the step-wise nature of T1D development and generated tools for early diagnosis, monitoring and disease modification.
EDENT1FI now positions Europe as the leader in early interception of T1D. Our goals are to identify individuals at earlier, pre-clinical stages, dramatically reducing clinical severity at T1D diagnosis and providing the opportunity for interventions with disease modifying therapies to delay or prevent clinical T1D. Spurred by the success of our collaborations in model European childhood screening activities and clinical networks in GPPAD and INNODIA, EDENT1FI will: establish harmonised islet autoantibody surveillance programmes to screen 200,000 children/adolescents across Europe; assess the psychosocial, medical and economic impact of screening in diverse European health systems/populations including underserved families; use state of the art metabolic sensors and biomarkers to optimise monitoring schedules for early-stage (pre-clinical) T1D aligned to maximising compliance and identifying disease progression strata; design SMART trials to expedite evaluation of disease modifying therapies; and inform and educate the public, healthcare professionals, and regulatory authorities of the new paradigms in T1D diagnosis and care.
To achieve this, EDENT1FI assembles academic, clinical and industry expertise in screening, clinical care, biomarkers, machine learning, population outreach, ethics, regulatory affairs and policy to accelerate evidence-based early T1D screening into regular healthcare in Europe. The success of these activities will promote early diagnosis and prevention pathways for other chronic childhood diseases.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Katholieke Universiteit Leuven | Leuven | Belgium | Coordinator |
| Medizinische Universitat Graz | Graz | Austria | Participant |
| European Diabetes Forum | Brussels | Belgium | Participant |
| Imcyse SA | Liège | Belgium | Participant |
| Medtronic International Trading SARL | Tolochenaz | Switzerland | Associatedpartner |
| MiniMed International Trading Sarl | Tolochenaz | Switzerland | Associatedpartner |
| Fakultni Nemocnice Motol a Homolka | Praha 5 | Czechia | Participant |
| Hannoversche Kinderheilanstalt | Hannover | Germany | Participant |
| Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt GmbH | Neuherberg | Germany | Participant |
| Sanofi-Aventis Deutschland GmbH | Frankfurt Am Main | Germany | Participant |
| Technische Universitaet Dresden | Dresden | Germany | Participant |
| Novo Nordisk A/s | Bagsvaerd | Denmark | Participant |
| Region Hovedstaden | Hillerod | Denmark | Participant |
| Tampereen Korkeakoulusaatio Sr | Tampere | Finland | Participant |
| Turun Yliopisto | Turku | Finland | Participant |
| Sanofi Winthrop Industrie | Gentilly | France | Associatedpartner |
| Sanofi-Aventis Recherche & Developpement | Gentilly | France | Associatedpartner |
| Ospedale San Raffaele SRL | Milano | Italy | Participant |
| Universita Degli Studi Di Siena | Siena | Italy | Participant |
| Critical Path Institute Stichting | Amsterdam | Netherlands | Associatedpartner |
| Medtronic Bakken Research Center B.v. | Maastricht | Netherlands | Participant |
| MiniMed Netherlands B.V. | Heerlen | Netherlands | Participant |
| Slaski Uniwersytet Medyczny W Katowicach | Katowice | Poland | Participant |
| Warszawski Uniwersytet Medyczny | Warszawa | Poland | Participant |
| Associacao Protectora Dos Diabeticos De Portugal | Lisboa | Portugal | Participant |
| Aventis Pharma Limited UK | Reading | United Kingdom | Associatedpartner |
| Cardiff University | Cardiff | United Kingdom | Associatedpartner |
| Digostics Limited | Didcot | United Kingdom | Associatedpartner |
| King's College London | London | United Kingdom | Associatedpartner |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
| The University of Birmingham | Birmingham | United Kingdom | Associatedpartner |
| Breakthrough T1d | New York | United States | Participant |
| Diabetomics, Inc. | Beaverton | United States | Associatedpartner |
| Medtronic MiniMed, Inc. | Northridge | United States | Associatedpartner |
| Provention Bio Inc | Red Bank | United States | Associatedpartner |
| Sanofi US Services Inc. | Cambridge, Massachusetts | United States | Associatedpartner |
| The Leona M. and Harry B. Helmsley Charitable Trust | New York | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI